News for Xenon Pharmaceuticals Inc. (XENE)

On February 28, 2025, FMR LLC (Trades, Portfolio), a prominent investment firm, executed a noteworthy transaction involving Xenon Pharmaceuticals Inc. The firm

Release Date: February 27, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Xenon Pharma

Comprehensive SWOT analysis based on Xenon Pharmaceuticals Inc's latest SEC 10-K filing.Insight into the company's financial health, innovative pipeline, and m

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NXENE.OQ - Xenon Pharmaceuticals IncQ4 2024 Xenon Pharmaceuticals Inc Earnings CallFeb 27, 2025

Xenon Pharmaceuticals Inc (XENE), a neuroscience-focused biopharmaceutical company, has released a business update and financial results for the fourth quarter

**media[552837]**

Xenon Pharmaceuticals Inc (XENE) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $0.33 million, and the ea

On February 18, 2025, COMMODORE CAPITAL LP (Trades, Portfolio) made a significant move by acquiring 5,825,000 shares of Solid Biosciences Inc (NASDAQ: SLDB) at

Xenon Pharmaceuticals Inc (XENE), a leading neuroscience-focused biopharmaceutical company, announced on February 25, 2025, that it will present at the 45th Ann

**media[550218]**

Xenon Pharmaceuticals Inc (XENE), a neuroscience-focused biopharmaceutical company, has announced that it will release its fourth quarter 2024 financial results

**media[546142]**

On December 31, 2024, COMMODORE CAPITAL LP (Trades, Portfolio) executed a substantial reduction in its holdings of Nkarta Inc (NKTX). The firm decreased its pos

On December 31, 2024, COMMODORE CAPITAL LP (Trades, Portfolio) executed a significant transaction involving Celcuity Inc (CELC), reducing its holdings by 426,68

On December 31, 2024, BRAIDWELL LP (Trades, Portfolio) executed a significant transaction involving the acquisition of shares in DBV Technologies SA. The firm a

Significant Transaction by COMMODORE CAPITAL LP (Trades, Portfolio) On December 31, 2024, COMMODORE CAPITAL LP (Trades, Portfolio) executed a noteworthy transac

Transaction Overview On February 7, 2025, COMMODORE CAPITAL LP (Trades, Portfolio) made a significant move by acquiring additional shares in Nurix Therapeutics

Xenon has promising Phase 2 data for MDD treatment, robust financials, and a potential in niche markets, despite premium valuation. See more on XENE stock here.

Summary Xenon Pharmaceuticals Inc (XENE), a leading neuroscience-focused biopharmaceutical company, announced its participation in the 43rd Annual J.P. Morgan H